Engineering cell lines for production of replication defective HSV-1 gene therapy vectors

Biotechnology and Bioengineering

Volumn 102, Issue 4, 2009, Pages 1087-1097

  Grant, Kyle G ^a   Krisky, David M ^b   Ataai, Mohammed M ^a   Glorioso III, Joseph C ^c  

^a University of Pittsburgh   (United States)

^b Diamyd Medical AB ^*  (Sweden)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Complementing cell line; Gene therapy; HSV 1; Viral vector production

Indexed keywords

CELLULAR GENOMES; CLINICAL USE; COMPLEMENTATION; COMPLEMENTING CELL LINE; CYTOTOXIC; ENGINEERING CELLS; GENE THERAPY; HERPES SIMPLEX VIRUS TYPE 1; HSV-1; LARGE SCALE MANUFACTURES; LYTIC FUNCTIONS; PRODUCTION CELLS; STRUCTURAL PROTEINS; TRANS-GENES; TRANSCRIPTIONAL CONTROLS; VECTOR PARTICLES; VECTOR PROPAGATION; VERO CELLS; VIRAL GENES; VIRAL VECTOR PRODUCTION; VIRUS REPLICATIONS; WILD TYPES;

BIOACTIVITY; CELL CULTURE; CELL GROWTH; GENE EXPRESSION; GENETIC ENGINEERING; GROWTH KINETICS; VIRUSES;

VECTORS;

GENE PRODUCT; HERPES SIMPLEX VIRUS 1 VECTOR; PROTEIN VP16; UNCLASSIFIED DRUG; VIRUS VECTOR; HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4; ICP27 PROTEIN, HUMAN HERPESVIRUS 1; IMMEDIATE EARLY PROTEIN;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; ENHANCER REGION; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENETIC COMPLEMENTATION; HERPES SIMPLEX VIRUS 1; ICP27 GENE; ICP4 GENE; IMMEDIATE EARLY GENE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TRANSGENE; VERO CELL; VIRAL GENE THERAPY; VIROGENESIS; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; WILD TYPE; ANIMAL; BIOTECHNOLOGY; CERCOPITHECUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY;

HUMAN HERPESVIRUS 1;

ANIMALS; BIOTECHNOLOGY; CERCOPITHECUS AETHIOPS; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; IMMEDIATE-EARLY PROTEINS; VERO CELLS; VIRUS REPLICATION;

EID: 60549094210     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22123     Document Type: Article

References (46)

1. apRhys CM, Ciufo DM, O'Neill EA, Kelly TJ, Hayward GS. 1989. Overlapping octamer and TAATGARAT motifs in the VF65-response elements in herpes simplex virus immediate-early promoters represent independent binding sites for cellular nuclear factor III. J Virol 63(6): 2798-2812.
2. Berges BK, Wolfe JH, Fraser NW. 2005. Stable levels oflong-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Mol Ther 12(6):1111-1119.
3. Bleckwenn NA, Bentley WE, Shiloach J. 2005. Evaluation of production parameters with the vaccinia virus expression system using microcar- rier attached HeLa cells. Biotechnol Prog 21(2):554-561.
4. Bruni R, Fineschi B, Ogle WO, Roizman B. 1999. A novel cellular protein, p60, interacting with both herpes simplex virus 1 regulatory proteins ICP22 and ICP0 is modified in a cell-type-specific manner and Is recruited to the nucleus after infection. J Virol 73(5):3810-3817.
5. Chattopadhyay M, Mata M, Goss J, Wolfe D, Huang S, Glorioso JC, Fink DJ. 2007. Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 50(7):1550-1558.
6. DeLuca NA, Schaffer PA. 1988. Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4. J Virol 62(3):732-743.
7. Douville P, Hagmann M, Georgiev O, Schaffner W. 1995. Positive and negative regulation at the herpes simplex virus ICP4 and ICP0 TAAT- GARAT motifs. Virology 207(1):107-116.
8. Everett RD. 1984. Trans activation of transcription by herpes virus products: Requirement for two HSV-1 immediate-early polypeptides for maximum activity. EMBO J 3(13):3135-3141.
9. Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio A, Naldini L. 2001. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 12(8):981 -997.
10. Fields BN, Knipe DM, Howley PM, Griffin DE. 2001. Fields virology, 4th edition. Philadelphia: Lippincott Williams & Wilkins. p 2 v. (xix, 3087, I-72).
11. Frampton AR Jr, Goins WF, Nakano K, Burton EA, Glorioso JC. 2005. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 12(11):891-901.
12. Gaffney DF, McLauchlan J, Whitton JL, Clements JB. 1985. A modular system for the assay of transcription regulatory signals: The sequence TAATGARAT is required for herpes simplex virus immediate early gene activation. Nucleic Acids Res 13(21):7847-7863.
13. Gelman IH, Silverstein S. 1985. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. Proc Natl Acad Sci USA 82(16):5265-5269.
14. Gelman IH, Silverstein S. 1986. Co-ordinate regulation of herpes simplex virus gene expression is mediated by the functional interaction of two immediate early gene products. J Mol Biol 191(3):395-409.
15. Goins WF, Krisky DM, Wolfe DP, Fink DJ, Glorioso JC. 2002. Development of replication-defective herpes simplex virus vectors. Methods Mol Med 69:481-507.
16. Hadjipanayis CG, DeLuca NA. 2005. Inhibition of DNA repair by a herpes simplex virus vector enhances the radiosensitivity of human glioblas- toma cells. Cancer Res 65(12):5310-5316.
17. Hao S, Mata M, Glorioso JC, Fink DJ. 2007. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 14(13):1010-1016.
18. Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. 2005. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracra- nial murine glioma model. Neuro Oncol 7(3):213-224.
19. Hennes-Stegmann B, Schroder CH. 1982. Low infectivity of HSV-1 DNA caused by defective-interfering genomes. J Gen Virol 63(2):307-314.
20. Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO. 2000. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 1(4):347-357.
21. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. 1999. A packaging cell line for lentivirus vectors. J Virol 73(1):576-584.
22. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso JC. 1998a. Development of herpes simplex virus replication- defective multigene vectors for combination gene therapy applications. Gene Ther 5(11):1517-1530.
23. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC. 1998b. Deletion ofmultiple immediate- early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 5(12):1593-1603.
24. Kwun HJ, Yim SW, Lee DH, Jang KL. 1999. Activation of the thymidine kinase promoter by herpes simplex virus type 1 immediate early proteins. Mol Cells 9(3):277-280.
25. Lewandoski M. 2001. Conditional control of gene expression in the mouse. Nat Rev Genet 2(10):743-755.
26. Lilley CE, Groutsi F, Han Z, Palmer JA, Anderson PN, Latchman DS, Coffin RS. 2001. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J Virol 75(9):4343-4356.
27. Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M, Fink DJ. 2004. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther 10(1):57-66.
28. Lium EK, Panagiotidis CA, Wen X, Silverstein S. 1996. Repression of the alpha0 gene by ICP4 during a productive herpes simplex virus infection. J Virol 70(6):3488-3496.
29. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF, Fink DJ, Glorioso JC. 1996. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 93(21):11319-11320.
30. Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. 2006. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 17(1):20-30.
31. Ozuer A, Wechuck JB, Goins WF, Wolfe D, Glorioso JC, Ataai MM. 2002a. Effect ofgenetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng 77(6): 685-692.
32. Ozuer A, Wechuck JB, Russell B, Wolfe D, Goins WF, Glorioso JC, Ataai MM. 2002b. Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnol Prog 18(3):476-482.
33. Preston CM. 1979. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 29(1):275-284.
34. Resnick J, Boyd BA, Haffey ML. 1989. DNA binding by the herpes simplex virus type 1 ICP4 protein is necessary for efficient down regulation of the ICP0 promoter. J Virol 63(6):2497-2503.
35. Sacks WR, Greene CC, Aschman DP, Schaffer PA. 1985. Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J Virol 55(3):796-805.
36. Samaniego LA, Wu N, DeLuca NA. 1997. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 71(6):4614-4625.
37. Sandri-Goldin RM. 2001. Nuclear export of herpes virus RNA. Curr Top Microbiol Immunol 259:2-23.
38. Sandri-Goldin RM. 2004. Viral regulation of mRNA export. J Virol 78(9): 4389-4396.
39. Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC, Yoshimura N. 2004. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 53(10):2723-2730.
40. SchroderCH, Furst B, Weise K, GrayCP. 1984. A study of interfering herpes simplex virus DNA preparations containing defective genomes ofeither class I or II and the identification of minimal requirements for interference. J Gen Virol 65(Pt 3):493-506.
41. Smith CA, Bates P, Rivera-Gonzalez R, Gu B, DeLuca NA. 1993. ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB. J Virol 67(8):4676-4687.
42. Smith RW, Malik P, Clements JB. 2005. The herpes simplex virus ICP27 protein: A multifunctional post-transcriptional regulator of gene expression. Biochem Soc Trans 33: (Pt 3): 499-501.
43. Su YH, Zhang X, Aiamkitsumrit B, Tang Q, Maul G, Fraser NW, BlockTM. 2006a. The stability of herpes simplex virus type I genomes in infected Vero cells undergoing viral induced apoptosis. J Neurovirol 12(5):375-386.
44. Su YH, Zhang X, Wang X, Fraser NW, Block TM. 2006b. Evidence that the immediate-early gene product ICP4 is necessary for the genome of the herpes simplex virus type 1 ICP4 deletion mutant strain d120 to circularize in infected cells. J Virol 80(23):11589-11597.
45. Thornton B, McEntee ID, Griffiths B. 1985. Production of herpes simplex virus from MRC-5 cells grown in a glass bead culture system. Dev Biol Stand 60:475-481.
46. Yao F, Schaffer PA. 1995. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol 69(10):6249-6258.